A Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of PUR3100, a Novel Dry Powder Formulation of Dihydroergotamine for Oral Inhalation, in Healthy Adults.

被引：0

作者：

Wasilewski, M. ^{[1
]}

Bodie, S. ^{[1
]}

Gonzalez, Nelson A. ^{[1
]}

Clayton, R. ^{[1
]}

Curran, A. ^{[1
]}

机构：

[1] Pulmatrix Inc, 99 Hayden Ave,Suite 390, Lexington, MA USA

来源：

HEADACHE | 2023年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-05

引用

页码：114 / 115

页数：2

共 50 条

[31] A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
Nagy, Andras
Duff, Kimberly
Bauer, Alexander
Okonneh, Fred
Rondon, Juan Carlos
Yel, Leman
Li, Zhaoyang
JOURNAL OF CLINICAL IMMUNOLOGY, 2024, 44 (01)
[32] A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
Andras Nagy
Kimberly Duff
Alexander Bauer
Fred Okonneh
Juan Carlos Rondon
Leman Yel
Zhaoyang Li
Journal of Clinical Immunology, 2024, 44
[33] A PHASE 1/2, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IGA NEPHROPATHY
Barratt, Jonathan
Schwartz, Brian
Sorensen, Bess
Macdonald, Margaret
Tolentino, Jerlyn
Lo, Jeannette
King, Andrew
Iyer, Sai Prasad N.
Glicklich, Alan
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I141 - I142
[34] Safety, Tolerability, and Pharmacokinetics of a Novel Oral Phosphodiesterase 4 Inhibitor, ME3183: First-in-Human Phase 1 Study
Kato, Seiji
Cho, Naoki
Koresawa, Tomokazu
Otake, Kazunari
Kano, Akiko
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (04): : 341 - 348
[35] A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
Albrecht, Detlef
Iwashima, Mic
Dillon, Debbie
Harris, Stuart
Levy, Jeff
HEADACHE, 2020, 60 (04): : 701 - 712
[36] Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
Kansagra, Kevinkumar A.
Parmar, Deven
Jani, Rajendra H.
Srinivas, Nuggehally R.
Lickliter, Jason
Patel, Harilal V.
Parikh, Devang P.
Heading, Heather
Patel, Hardik B.
Gupta, Rahul J.
Shah, Chintan Y.
Patel, Maulik R.
Dholakia, Vyom N.
Sukhadiya, Raghav
Jain, Mukul R.
Parmar, Krupi V.
Barot, Kinjal
CLINICAL PHARMACOKINETICS, 2018, 57 (01) : 87 - 102
[37] A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Two Formulations of a Novel Nav1.6 Sodium Channnel Blocker (XEN901) in Healthy Adult Subjects.
Beatch, Gregory
Namdari, Rostam
Cadieux, Jay
Kato, Heather
Aycardi, Ernesto
NEUROLOGY, 2020, 94 (15)
[38] Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers
Kevinkumar A. Kansagra
Deven Parmar
Rajendra H. Jani
Nuggehally R. Srinivas
Jason Lickliter
Harilal V. Patel
Devang P. Parikh
Heather Heading
Hardik B. Patel
Rahul J. Gupta
Chintan Y. Shah
Maulik R. Patel
Vyom N. Dholakia
Raghav Sukhadiya
Mukul R. Jain
Krupi V. Parmar
Kinjal Barot
Clinical Pharmacokinetics, 2018, 57 : 87 - 102
[39] A phase 1, single-center, open label, dose-rising clinical trial to evaluate the pharmacokinetics, safety and tolerability of treprostinil inhalation powder (TreT) in healthy normal volunteers
Smith, Peter
Watkins, Catherine
Kraft, Kelly
Grant, Marshall
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[40] Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study
Fraz A. Ismat
Helen H. Usansky
Raul Villa
Jun Zou
Ariel Teper
Advances in Therapy, 2022, 39 : 5144 - 5157

← 1 2 3 4 5 →